Previous 10 | Next 10 |
home / stock / polbf / polbf news
Targeting an infectious disease with a high mortality rate and growing incidence driven by climate change LONDON, UK / ACCESSWIRE / September 21, 2022 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF)('Poolbeg' or the 'Company'), a clinical stage infectious disease pharmaceutical company wit...
LONDON, UK / ACCESSWIRE / September 12, 2022 / Poolbeg Pharma (AIM:POLB, OTCQB:POLBF, 'Poolbeg' or the 'Company'), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that the Company's Chairman, Cathal Friel, will be attending th...
LONDON, UK / ACCESSWIRE / July 29, 2022 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) ('Poolbeg' or the 'Company'), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, has appointed Singer Capital Markets as Joint Broker with immediate effe...
Major milestone reached as POLB 001 human challenge clinical trial ready to commence Regulatory approval gives green light for trial to proceed LONDON, UK / ACCESSWIRE / July 20, 2022 / Poolbeg Pharma (Poolbeg Pharma plc) (AIM:POLB)(OTCQB:POLBF), ('Poolbeg' or the 'Company'), a...
OneThree Biotech completes build and optimisation of AI model for RSV data - results to come in H2 First time AI used to model RSV with complete longitudinal disease data LONDON, UK / ACCESSWIRE / June 27, 2022 / Poolbeg Pharma (AIM:POLB, OTCQB:POLBF, 'Poolbeg' or the 'Company'),...
NEW YORK, June 24, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the June 23 r d Life Sciences Investor Forum are now available for on-demand viewing. REGISTER NOW OR LOG...
NEW YORK, June 21, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, in partnership with Zacks Small-Cap Research, today announced the agenda for the upcoming Life Sciences Investor Forum to be held on June 23 rd . Individual inve...
NEW YORK, June 21, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, in partnership with Zacks Small-Cap Research, today announced the agenda for the upcoming Life Sciences Investor Forum to be held on June 23 rd . Individual inve...
Further Expansion of IP Portfolio Enhancing Protection of Poolbeg's Growing Pipeline LONDON, UK / ACCESSWIRE / May 26, 2022 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), 'Poolbeg' or the 'Company'), a clinical stage infectious disease pharmaceutical company with a unique capital lig...
Update on POLB 001 Clinical Development GMP manufacturing contract signed ensuring ample supply of POLB 001 for clinical development and for use in investigating further potential disease indications LONDON, UK / ACCESSWIRE / May 12, 2022 / Poolbeg Pharma (AIM:POLB), (OTCQB:POLBF), ...
News, Short Squeeze, Breakout and More Instantly...
Poolbeg Pharma plc Ord GBP 0.0002 Company Name:
POLBF Stock Symbol:
OTCMKTS Market:
Poolbeg Pharma plc Ord GBP 0.0002 Website:
LONDON, UK / ACCESSWIRE / July 26, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) 'Poolbeg' or the 'Company'), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that it is voluntaril...
LONDON, UNITED KINGDOM / ACCESSWIRE / July 10, 2024 / TR-1: Standard form for notification of major holdings This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the U...
Change of Registered Address LONDON, UK / ACCESSWIRE / July 2, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), ('Poolbeg' or the 'Company'), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medi...